The Epoch Times
The Epoch Times
AD
The Epoch Times
Chinese Regime

Chinese COVID-19 Vaccines Under Spotlight After Woman Censored for Posting About Death Following Sinopharm Shot

Google LogoMark Us Preferred on Google
Chinese COVID-19 Vaccines Under Spotlight After Woman Censored for Posting About Death Following Sinopharm Shot
A student (L) reacts as she receives the Sinopharm COVID-19 vaccine at a high school in Shenyang in China's northeastern Liaoning Province on July 28, 2021. STR/AFP via Getty Images
Terri Wu
Terri Wu
9/3/2021|Updated: 9/4/2021

The censoring of a woman who posted about the death of her mother after receiving a COVID-19 vaccine has recently caused a stir in China, prompting further scrutiny on the effectiveness of Chinese-made vaccines.

On Aug. 24, a woman with the handle TomoJiangJiang posted on Weibo, a Twitter-like platform, that after her mother took her first Sinopharm COVID-19 shot on Mar. 26, she developed a drug-induced rash and skin hemorrhages on Mar. 31, and eventually died on June 30.

Google LogoMark Us Preferred on Google
Terri Wu
Terri Wu
Author
Terri Wu is a Washington-based freelance reporter for The Epoch Times covering education and China-related issues. Send tips to [email protected].
Author’s Selected Articles
Entangled Combat: The Chinese Style of Competition Washington Should Understand
May 12, 2026
Entangled Combat: The Chinese Style of Competition Washington Should Understand
How US Is Using Iran War to Squeeze China Ahead of Trump–Xi Summit
May 11, 2026
How US Is Using Iran War to Squeeze China Ahead of Trump–Xi Summit
On Shadow Fleets, ‘Teapots,’ and Layered Approaches to Avoiding Sanctions
May 05, 2026
On Shadow Fleets, ‘Teapots,’ and Layered Approaches to Avoiding Sanctions
Why a Once-Taboo Topic on China Is Now a US Bestseller
Apr 28, 2026
Why a Once-Taboo Topic on China Is Now a US Bestseller
Related Topics
sinopharm
Chinese vaccine
China COVID-19
AD
Add to My List
Save
The Epoch Times
Copyright © 2000 - 2026 The Epoch Times Association Inc. All Rights Reserved.